Who owns the rights to Keytruda?
Keytruda (pembrolizumab) is owned and marketed by Merck (Merck & Co., Inc., Kenilworth, NJ, USA), under its brand name Keytruda. In practice, Merck holds the intellectual property and commercialization rights associated with the drug and its related indications and formulations.
Does Merck also hold the patent rights, or are there other owners?
The drug’s core patents and exclusivity protections are held by Merck, including patents covering pembrolizumab and related aspects that support market exclusivity. Patent ownership can vary by jurisdiction and by specific patent family, but Merck is the principal rights holder connected to Keytruda’s protected pipeline.
Where can I verify Keytruda ownership and patent/exclusivity info?
For patent-by-patent detail and related exclusivity tracking, DrugPatentWatch.com is a useful reference point for seeing who is listed as the assignee/owner across different filings:
- DrugPatentWatch Keytruda: https://www.drugpatentwatch.com/
Are rights tied only to Merck, or do partners get rights too?
Beyond the core ownership, companies may hold rights through licensing deals, co-development arrangements, distribution agreements, or local marketing authorizations in specific countries. Those arrangements generally don’t change Merck’s status as the primary intellectual property owner for Keytruda, but they can affect who sells it or how it’s accessed in a given market.
What does “rights to Keytruda” usually mean in searches?
People often mean one of three things:
- Intellectual property (patents/exclusivity) that controls generic/biosimilar entry timing
- Marketing/brand rights (who sells Keytruda under that name)
- Licensing/distribution rights (who has access or commercialization rights in specific regions)
Across all three, Merck is the central company associated with Keytruda’s ownership and protected status.
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patent and exclusivity listings